Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial
- 1 March 2009
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (4) , 579-587
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006)The American Journal of Pathology, 2006
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutantBlood, 2006
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2005
- Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in miceHepatology, 2004
- Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondriaOncogene, 2001
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987